Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for...
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer,...
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen...
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in...
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd...
KRRO-110 is the first RNA editing oligonucleotide candidate from Korro™s proprietary OPERA„¢ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT)...
Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
Tim Pearson, CEO of Carrick Therapeutics and ex-CFO of TESARO, will join as Director contingent on the close of the proposed merger with FrequencyTodd Chappell is elevated to role of Chief Operating...